Uso de psicofármacos para síntomas neuropsiquiátricos en pacientes hospitalizados con COVID-19

Autores/as

  • Glauco Valdivieso-Jiménez Hospital de Emergencias Villa El Salvador, Servicio de Salud Mental, Lima, Perú; Instituto Peruano para el Estudio y Abordaje Integral de la Personalidad, Lima, Perú https://orcid.org/0000-0001-8561-6768

DOI:

https://doi.org/10.24265/horizmed.2021.v21n2.13

Palabras clave:

Psicotrópicos, Hospitalización, Coronavirus, COVID-19

Resumen

La pandemia por la COVID-19 es la actual crisis sanitaria mundial que, hasta la fecha, ha cobrado miles de vidas en la mayoría de los países. Desde inicios del 2020 se estudia el comportamiento epidemiológico y clínico de este virus, así como también se han planteado esquemas terapéuticos que logren eliminar el virus, per se, y sus complicaciones a nivel sistémico. Sin embargo, los pacientes hospitalizados por esta infección también presentan síntomas neuropsiquiátricos, por lo que el manejo farmacológico requiere de consideraciones especiales al momento de su prescripción. Los síntomas neuropsiquiátricos secundarios más comunes en un cuadro de COVID-19 son ansiedad, insomnio, ánimo deprimido, delirio y agitación. La elección de psicofármacos debe basarse en el principio de no generar más daño, y valorar el riesgo-beneficio, el perfil farmacológico, las posibles interacciones y condiciones médicas previas del paciente.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020; 25(3): 278-80.

Zhang L, Liu Y. Potential interventions for novel coronavirus in China: Uso de psicofármacos para síntomas neuropsiquiátricos en pacientes hospitalizados con COVID-19 a systematic review. J Med Virol. 2020; 92(5): 479-90.

Gobierno del Estado Peruano. Coronavirus en el Perú: casos confirmados [Internet]. Lima; 2020. Disponible en: https://www.gob.pe/

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178: 104787.

Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect. 2020; 35: 100684.

Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020; S0140-6736(20): 31180-6.

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): a review. JAMA. 2020; 323(18): 1824-36.

Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020; 55(5): 105955.

Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020; 7(7): 611-27.

Guo Q, Zheng Y, Shi J, Wang J, Li G, Li C, et al. Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: a mixed-method study. Brain Behav Immun. 2020; 88: 17-27.

Lovell N, Maddocks M, Etkind SN, Taylor K, Carey I, Vora V, et al. Characteristics, symptom management and outcomes of 101 patients with COVID-19 referred for hospital palliative care. J Pain Symptom Manage. 2020; S0885-3924(20): 30211-6.

Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, Iannetta M, et al. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain Behav Immun. 2020; 88: 11-6.

Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2011; 38(1): 10-20.

Harrold LR, John A, Reed GW, Haselkorn T, Karki C, Li Y, et al. Impact of Tocilizumab monotherapy on clinical and patient-reported quality of-life outcomes in patients with rheumatoid arthritis. Rheumatol Ther. 2017; 4(2): 405-17.

Abers MS, Shandera WX, Kass JS. Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs. 2014; 28(2): 131-45.

Ginsberg DL. Azithromycin-induced psychotic depression and catatonia. Prim Psychiatry. 2006; 13(5): 22-6.

Dubovsky AN, Arvikar S, Stern TA, Axelrod L. The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited. Psychosomatics. 2012; 53(2): 103-15.

National Institute for Health and Care Excellence (NICE) in collaboration with NHS England and NHS Improvement. Managing COVID-19 symptoms (including at the end of life) in the community: summary of NICE guidelines. BMJ. 2020; 369: m1461.

Esteve Arríen A, Aguera Ortiz L, Manzano Palomo S. Manejo farmacológico de trastornos psicóticos en personas mayores con tratamiento de la infección por COVID19: interacciones y recomendaciones terapéuticas [Internet]. España; 2020. Disponible en:https://www.fesemi.org/sites/default/files/documentos/19.pdf

Khawam E, Khouli M, Pozuelo L. Treating acute anxiety in patients with Covid-19. Cleve Clin J Med. 2020.

University of Liverpool. Interactions with experimental COVID-19 Therapies [Internet]. 2020. Disponible en: https://www.covid19- druginteractions.org/

MedScape. Drug Interaction Checker [Internet]. 2020. Disponible en: https://reference.medscape.com/drug-interactionchecker

Huremović D. Psychiatry of Pandemics: a mental health response to infection outbreak. Springer Nature: Switzerland; 2019.

Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: melatonin as a potential adjuvant treatment. Life Sci. 2020; 250: 117583.

Zhang K, Zhou X, Liu H, Hashimoto K. Treatment concerns for psychiatric symptoms in patients with COVID-19 with or without psychiatric disorders. Br J Psychiatry. 2020; 217(1): 351.

Lewis SR, Pritchard MW, Schofield-Robinson OJ, Alderson P, Smith AF. Melatonin for the promotion of sleep in adults in the intensive care unit. Cochrane Database Syst Rev. 2018; 5(5): CD012455.

Anttila SAK, Leinonen EVJ. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001; 7(3): 249-64.

Luykx JJ, Van Veen SMP, Risselada A, Naarding P, Tijdink JK, Vinkers CH. Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic. Br J Psychiatry. 2020; 217(3): 471-4.

Livingston RL, Zucker DK, Isenberg K, Wetzel RD. Tricyclic antidepressants and delirium. J Clin Psychiatry. 1983; 44(5): 173-6.

Kotfis K, Williams-Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Crit Care. 2020; 24(1): 176.

Baller EB, Hogan CS, Fusunyan MA, Ivkovic A, Luccarelli JW, Madva E, et al. Neurocovid: pharmacological recommendations for delirium associated with COVID-19. Psychosomatics. 2020.

Manjunatha N, Naveen Kumar C, Bada Math S. Mental health in the times of COVID-19 pandemic: Guidance for general medical and specialised mental health care settings. National Department of Psychiatry National Institute of Mental Health & Neurosciences (NIMHANS). 2020.

Jernigan MG, Kipp GM, Rather A, Jenkins MT, Chung AM. Clinical implications and management of drug-drug interactions between antiretroviral agents and psychotropic medications. Ment Health Clin. 2013; 2(9): 274-85.

Bilbul M, Paparone P, Kim AM, Mutalik S, Ernst CL. Psychopharmacology of COVID-19. Psychosomatics. 2020.

##submission.downloads##

Publicado

2021-05-21

Cómo citar

1.
Valdivieso-Jiménez G. Uso de psicofármacos para síntomas neuropsiquiátricos en pacientes hospitalizados con COVID-19. Horiz Med (Lima) [Internet]. 21 de mayo de 2021 [citado 2 de julio de 2022];21(2):e1272. Disponible en: https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/1272

Número

Sección

Artículos de revisión